Centessa Pharmaceuticals (CNTA) Competitors

$40.50 0.00 (0.00%)

As of 06/25/2026

CNTA vs. INSM, BNTX, VTRS, GMAB, and ASND

Should you buy Centessa Pharmaceuticals stock or one of its competitors? MarketBeat compares Centessa Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Centessa Pharmaceuticals include Insmed (INSM), BioNTech (BNTX), Viatris (VTRS), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

How does Centessa Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Insmed had 13 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 13 mentions for Insmed and 0 mentions for Centessa Pharmaceuticals. Insmed's average media sentiment score of 0.94 beat Centessa Pharmaceuticals' score of 0.00 indicating that Insmed is being referred to more favorably in the media.

Company	Overall Sentiment
Insmed	Positive
Centessa Pharmaceuticals	Neutral

Insmed currently has a consensus price target of $211.00, indicating a potential upside of 93.33%. Centessa Pharmaceuticals has a consensus price target of $41.33, indicating a potential upside of 2.06%. Given Insmed's stronger consensus rating and higher possible upside, research analysts plainly believe Insmed is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Insmed has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Centessa Pharmaceuticals has lower revenue, but higher earnings than Insmed. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.01	-$1.28B	-$5.75	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

Centessa Pharmaceuticals has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Centessa Pharmaceuticals' return on equity of -60.37% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Summary

Insmed and Centessa Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, BioNTech had 6 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 6 mentions for BioNTech and 0 mentions for Centessa Pharmaceuticals. BioNTech's average media sentiment score of 1.06 beat Centessa Pharmaceuticals' score of 0.00 indicating that BioNTech is being referred to more favorably in the media.

Company	Overall Sentiment
BioNTech	Positive
Centessa Pharmaceuticals	Neutral

Centessa Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.02	-$1.29B	-$5.88	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

Centessa Pharmaceuticals has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

BioNTech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

BioNTech currently has a consensus price target of $129.13, suggesting a potential upside of 43.36%. Centessa Pharmaceuticals has a consensus price target of $41.33, suggesting a potential upside of 2.06%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Summary

BioNTech beats Centessa Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Centessa Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.33	-$3.51B	-$0.26	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

Viatris currently has a consensus price target of $17.50, indicating a potential upside of 6.77%. Centessa Pharmaceuticals has a consensus price target of $41.33, indicating a potential upside of 2.06%. Given Viatris' stronger consensus rating and higher probable upside, analysts clearly believe Viatris is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Centessa Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

In the previous week, Viatris had 3 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 3 mentions for Viatris and 0 mentions for Centessa Pharmaceuticals. Viatris' average media sentiment score of 1.10 beat Centessa Pharmaceuticals' score of 0.00 indicating that Viatris is being referred to more favorably in the media.

Company	Overall Sentiment
Viatris	Positive
Centessa Pharmaceuticals	Neutral

Viatris has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Viatris beats Centessa Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Genmab A/S?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Genmab A/S has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Genmab A/S	$3.72B	4.83	$963M	$1.32	21.82

Centessa Pharmaceuticals presently has a consensus price target of $41.33, indicating a potential upside of 2.06%. Genmab A/S has a consensus price target of $38.21, indicating a potential upside of 32.69%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Genmab A/S has a net margin of 21.05% compared to Centessa Pharmaceuticals' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Genmab A/S	21.05%	15.34%	8.94%

In the previous week, Genmab A/S had 5 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 5 mentions for Genmab A/S and 0 mentions for Centessa Pharmaceuticals. Genmab A/S's average media sentiment score of 1.16 beat Centessa Pharmaceuticals' score of 0.00 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Neutral
Genmab A/S	Positive

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Genmab A/S beats Centessa Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Centessa Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Centessa Pharmaceuticals has lower revenue, but higher earnings than Ascendis Pharma A/S. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.31	-$258M	$8.67	30.59
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

Ascendis Pharma A/S has a net margin of 57.87% compared to Centessa Pharmaceuticals' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Ascendis Pharma A/S currently has a consensus target price of $295.67, suggesting a potential upside of 11.48%. Centessa Pharmaceuticals has a consensus target price of $41.33, suggesting a potential upside of 2.06%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts clearly believe Ascendis Pharma A/S is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Ascendis Pharma A/S has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 0 mentions for Centessa Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.01 beat Centessa Pharmaceuticals' score of 0.00 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Ascendis Pharma A/S	Positive
Centessa Pharmaceuticals	Neutral

Summary

Ascendis Pharma A/S beats Centessa Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

Get Centessa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTA vs. The Competition

Export

Metric	Centessa Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.27B	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-22.63	19.17	27.11	24.26
Price / Sales	N/A	838.79	589.96	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	10.33	4.22	10.74	6.29
Net Income	-$197.53M	$64.26M	$3.58B	$330.66M
7 Day Performance	N/A	-3.58%	-2.11%	-1.35%
1 Month Performance	1.96%	2.12%	3.27%	-0.64%
1 Year Performance	167.68%	20.35%	26.31%	19.08%

Centessa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTA Centessa Pharmaceuticals	0.8296 of 5 stars	$40.50 flat	$41.33 +2.1%	N/A	$6.27B	N/A	N/A	200
INSM Insmed	4.1051 of 5 stars	$112.84 +1.2%	$211.86 +87.8%	+11.2%	$24.46B	$819.56M	N/A	1,664
BNTX BioNTech	4.5286 of 5 stars	$94.29 +0.4%	$129.56 +37.4%	-20.2%	$23.84B	$3.25B	N/A	7,807	Positive News
VTRS Viatris	2.7129 of 5 stars	$16.96 +1.0%	$17.50 +3.2%	+79.7%	$19.75B	$14.30B	N/A	30,000	Gap Down
GMAB Genmab A/S	4.5902 of 5 stars	$29.18 +4.2%	$38.21 +31.0%	+34.6%	$18.19B	$3.72B	22.11	3,029

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Centessa Pharmaceuticals (CNTA) Competitors

CNTA vs. INSM, BNTX, VTRS, GMAB, and ASND

How does Centessa Pharmaceuticals compare to Insmed?

Summary

How does Centessa Pharmaceuticals compare to BioNTech?

Summary

How does Centessa Pharmaceuticals compare to Viatris?

Summary

How does Centessa Pharmaceuticals compare to Genmab A/S?

Summary

How does Centessa Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTA vs. The Competition

Centessa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Centessa Pharmaceuticals (CNTA) Competitors

CNTA vs. INSM, BNTX, VTRS, GMAB, and ASND

How does Centessa Pharmaceuticals compare to Insmed?

Do institutionals & insiders have more ownership in INSM or CNTA?

Does the media refer more to INSM or CNTA?

Do analysts recommend INSM or CNTA?

Which has more risk & volatility, INSM or CNTA?

Which has better earnings and valuation, INSM or CNTA?

Is INSM or CNTA more profitable?

Summary

How does Centessa Pharmaceuticals compare to BioNTech?

Do institutionals and insiders believe in BNTX or CNTA?

Does the media refer more to BNTX or CNTA?

Which has preferable earnings and valuation, BNTX or CNTA?

Is BNTX or CNTA more profitable?

Which has more risk and volatility, BNTX or CNTA?

Do analysts recommend BNTX or CNTA?

Summary

How does Centessa Pharmaceuticals compare to Viatris?

Which has preferable valuation & earnings, VTRS or CNTA?

Do analysts recommend VTRS or CNTA?

Is VTRS or CNTA more profitable?

Does the media refer more to VTRS or CNTA?

Which has more volatility and risk, VTRS or CNTA?

Do insiders and institutionals have more ownership in VTRS or CNTA?

Summary

How does Centessa Pharmaceuticals compare to Genmab A/S?

Which has stronger earnings and valuation, CNTA or GMAB?

Do analysts recommend CNTA or GMAB?

Is CNTA or GMAB more profitable?

Does the media refer more to CNTA or GMAB?

Which has more risk & volatility, CNTA or GMAB?

Do institutionals & insiders have more ownership in CNTA or GMAB?

Summary

How does Centessa Pharmaceuticals compare to Ascendis Pharma A/S?

Do insiders and institutionals hold more shares of ASND or CNTA?

Which has stronger valuation & earnings, ASND or CNTA?

Is ASND or CNTA more profitable?

Do analysts prefer ASND or CNTA?

Which has more volatility and risk, ASND or CNTA?

Does the media favor ASND or CNTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTA vs. The Competition

Centessa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools